The research unit of the UCSF-Stanford CERSI stimulates innovative and collaborative research in regulatory science among FDA scientists, academic scientists, and scientists in the biotechnology and pharmaceutical industries. Particular attention is paid to research involving computational methods to integrate vast and multiple data sets in the evaluation of therapies that will lead to better quality and safer medical products for the health of the public.

Funding for collaborative science

The UCSF-Stanford CERSI will fund collaborative research projects that focus on “unmet needs” in regulatory science. A broad net will be cast to define the most critical problems in regulatory science that can be solved through collaborative research efforts; the center will fund research that addresses the most critical problems. Complementing the research program funded by the FDA is an Innovation in Regulatory Sciences Award from the Burroughs Wellcome Fund. This award is focused on using systems pharmacology approaches to identify the targets and mechanisms for drug-induced obesity, a major adverse event for many drugs including many neuropsychiatric agents. A copy of our Procedures for Initiating Collaborative Research Projects can be found here: PDF iconResearch Guidelines

Research environment of UCSF and Stanford

The center’s collaborative research unit engages top-tier researchers at UCSF and Stanford University to apply modern methods to problems in regulatory science.

Historically, UCSF has been the premier institution in quantitative pharmacology as it relates to drug discovery and development. UCSF pioneered pharmacokinetics and pharmacodynamics and computational drug discovery, which are used commonly in regulatory science. UCSF has continued to lead the pharmacological sciences with internationally renowned faculty members in pharmacogenomics, chemoinformatics, disease modeling, imaging and high throughput methodologies, and by forging strong research programs relevant to the discovery and development of therapeutics. The California Institute for Quantitative Biosciences-UCSF (QB3-UCSF) provides a home and resources for the recruitment of exceptional new faculty with quantitative skills.

Stanford University features a world-class Stanford Center for Biomedical Informatics Research, which recently pioneered the use of internet query logs, population health databases (e.g., FDA AERS Database), and electronic medical records from hospitals to identify adverse drug events and drug interactions.

Collaborations among Stanford University and UCSF scientists and the FDA are already under way for using new informatics methods for data fusion to construct safety profiles of drugs and for developing quantitative models to predict drug levels in the central nervous system. The collaborative research projects include a pilot project funding mechanism.

For Current Awardees: Please make sure to acknowledge the funding source for your project by including the following statement:

This publication/poster was made possible by Grant NumberU01FD004979/U01FD005978 from the FDA, which supports the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS or FDA.

Listing of Research Projects

Jump below to: Not Yet Completed or Completed.

Research Projects: Not Yet Completed

Research Project Title

Lead scientist at UCSF & Stanford University

FDA Collaborators​/​Non-federal entities collaborators

1. Role of Ancestry in Genetic Diagnostics

Snehit Prabhu, PhD (Stanford)

Adam Berger, PhD (CDRH/FDA)
Roselie Bright, ScD, Ms, PMP (OHI/FDA)
Elaine Johanson (OHI/FDA)
Samir Lababidi, PhD (OHI/FDA)
David Litwack, PhD (CDRH/FDA)
Zivana Tezak, PhD (CDRH/FDA)

2. Causes of Real-Life NGS Variability

Dmitri Petrov, PhD (Stanford)

Elaine Johanson (OHI/FDA)

3. Effects of Excipients in Generic Drugs Products on Intestinal Drug Transporters

Kathy Giacomini, PhD (UCSF)

Andrew Babiskin, PhD (CDER/FDA)
Sruthi King, PhD (CDER/FDA)
Zhanglin Ni, PhD (CDER/FDA)
Eleftheria Tsakalozou, PhD (CDER/FDA)
Liang Zhao, PhD (CDER/FDA)
Susan Zuk, MS (CDER/FDA)
4. OneSource Phase 2 Laura Esserman, MD, MBA (UCSF)
Mitra Rocca, Dipl. Inform. Med. (CDER/FDA)
Jacqueline Corrigan-Curay, JD, MD (CDER/FDA)
Dianne Paraoan (CDER/FDA)
Frank Weichold, MD, PhD (ORSI/FDA)
Paul Kluetz, MD (Oncology Center of Excellence/FDA)
Gideon (Scott) Gordon, PhD (CDER/OSP/FDA)

5. Safer Labeling of Pediatric Medications

Lee Sanders, MD (Stanford)
Bonnie Halpern-Felsher, PhD (Stanford)
Shelly Harris, MPH (CDER/FDA)
Grace Jones, PharmD (CDER/FDA)
Martin Mendoza, PhD (OMH/FDA)
Amanda Pike-McCrudden, MAA (CDER/FDA)
Lee Zwanziger (OC/FDA)

6. Patient Reported Outcomes for Minimally Invasive Glaucoma Surgery

Kuldev Singh, MD, MBA (Stanford)
Tianjing Li, MD, PhD (JHU)
Kay Dickerson, PhD (JHU)
Malvina Eydelman, MD (CDRH/FDA)
Michelle Tarver, MD, PhD (CDRH/FDA)

7. Comparing Qualitative and Quantitative Approaches to Eliciting Patient Preferences on Upper Limb Prostheses

Leslie Wilson, PhD (UCSF)

Heather Benz, PhD (CDRH/FDA)
Eugene Civillico, PhD (CDRH/FDA)
Martin Ho, MSc (CDRH/FDA)
Telba Irony, PhD (CBER/FDA)
Xuefeng Li, PhD (CDRH/FDA)
Anindita Saha (CDRH/FDA)

8. Developing an Operational Framework for Defining the Strength of Evidence in Therapeutic Development

Steve Goodman, MD, MHS, PhD (Stanford)

Telba Irony, PhD (CBER/FDA)
Tom Permutt, PhD (CDER/FDA)
Estelle Russek-Cohen, PhD (CDER/FDA)

9. Predicting Pediatric Dosing for Medical Countermeasures

Kathy Giacomini, PhD (UCSF)
Kathy Cheung, PharmD (UCSF)

Shiew Mei Huang, PhD (CDER/FDA)

10. Development of Thrombogenicity Testing Methods for Medical Devices with Large Blood-Contacting Surfaces

Shuvo Roy, PhD (UCSF)

Megan Jamiolkowski, PhD (CDRH/FDA)
Richard Malinauskas, PhD (CDRH/FDA)

11. Developing Frameworks and Tools for Integration of Digital Health Tools into Clinical Practice

Andrew Auerbach, MD (UCSF)

Bakul Patel, MS, MBA (CDRH/FDA)
Marisa Cruz, MD (CDRH/FDA)

12. An Unbiased Analysis of Identification and Assessment of Cas9/gRNA Potential Off-Target Sites in Clinical Development of Ex Vivo Manufactured Genome Edited Cell Products

Matthew Porteus, MD, PhD (Stanford)

Zhaohui Ye, PhD (CBER/FDA)

13. The Impact of Race and Ethnicity on Responses to Heart Failure Patient-Reported Outcome Measures

Courtney Lyles, PhD (UCSF)
Urmimala Sarkar, MD, MPH (UCSF)
Fraser Bocell, PhD (CDRH/FDA)
Michelle Tarver, MD PhD (CDRH/FDA)
Brittany Caldwell, PhD (CDRH/FDA)
Fraser Bocell, PhD (CDRH/FDA)
Annie Saha (CDRH/FDA)
Martin Ho, MSc (CDRH/FDA)

14. Adapting a Measure of Heart Failure to an Adolescent Population

Christopher Almond, MD, MPH (Stanford)
Jonathan Johnson, MD (Mayo Clinic)
Fraser Bocell, PhD (CDRH/FDA)
Vasum Peiris, MD, MPH (CDRH/FDA)
Michelle Tarver, MD, PhD (CDRH/FDA)
Brittany Caldwell, PhD (CDRH/FDA)
Annie Saha (CDRH/FDA)
Martin Ho (CDRH/FDA)

15. Healthy Citizen Hospital Pilot

Ida Sim, MD, PhD (UCSF)

Elaine Johanson (OHI/FDA)
Ameeta Parekh, PhD (CDER/FDA)

16. Multi-organ Microphysiological Systems for Modeling Clinical Drug Effects

Kevin Healy, PhD (UC Berkeley)
Edward Hsiao, MD, PhD (UCSF)
Alexandre Ribeiro, PhD (CDER/FDA)
David Strauss, MD, PhD (CDER/FDA)
17. Tissue Chips for Multipotent Stromal Cell Manufacturing
Ngan Huang, PhD (Stanford)
Kyung Sung, PhD (CBER/FDA)
18. Isolating Exosomes using a novel ExoTIC device from HIV-infected patient plasma and saliva
Utkan Demirci, PhD (Stanford)
Indira Hewlett, PhD (CBER/FDA)
Mohan Haleyurgirisetty, PhD (CBER/FDA)
Jiangqin Zhao, PhD (CBER/FDA)
19. Development and Evaluation of Computational Test Methods Leveraging Real-world and Simulated Datasets for Predictive Medical Device Alarm Algorithms
Xiao Hu, PhD (UCSF)
Christopher Scully, PhD (CDRH/FDA)
20. Advancing Computational Modeling in the Regulatory Evaluation of Spinal Fusion Cages
Jeffrey Lotz, PhD (UCSF)
Anton Dmitriev, PhD (CDRH/FDA)
Andrew Baumann, PhD (CDRH/FDA)

21. Evaluation of the impact of Genetic Variability on Drug Target Interactions using Structural Bioinformatics

Russ Altman, MD, PhD (Stanford)

Michael Pacanowski, PharmD, MPH (CDER/FDA)

Oluseyi Adeniyi, PhD (CDER/FDA)

Paula Hyland, PhD (CDER/FDA)

Ellis Christopher, PhD (CDER/FDA)

Rosane Charlab Orbach, PhD (CDER/FDA)

Robert Schuck, PhD (CDER/FDA)

22. Comprehensive Assessment of Sex Differential Smoking related Effects in Publicly Available Gene Expression Data

Russ Altman, MD, PhD (Stanford)

Bridget Nugent, PhD (OWH/FDA)

Patricia Bradfield (OWH/FDA)

Kaveeta Vasisht, MD, PharmD (OWH/FDA)

Ryan Conville, (OWH/FDA)

23. Development of New and Innovative Methods for Automated Reporting for CBER-Regulated Biological Products

Tina Hernandez-Boussard, PhD, MPH, MS (Stanford)

Barbee Whitaker, PhD (CBER/FDA)

Steven Anderson, PhD (MPP, CBER/FDA)

Artur Belov, PhD (CBER/FDA)

24. Development of New Machine Learning Algorithms to Quantify Treatment Effectiveness and Adverse Outcomes

James Zou, PhD (Stanford)

Steven Anderson, PhD, MPP (CBER/FDA)

Barbee Whitaker, PhD (CBER/FDA)

Alan Williams, PhD (CBER/FDA)

Gregory Pappas, MD, PHD (CBER/FDA)

Angela Moy (CBER/FDA)

25. Characterizing Risk-Benefit Tradeoff in Opioid-based Chronic Pain Treatment

Sean Mackey, MD, PhD (Stanford)

Michelle Tarver, MD, PhD (CDRH/OST/FDA)

Annie Saha (CDRH/OST/FDA)

David Gebben, PhD (CDRH/OST/FDA)

Heather Benz, PhD (CDRH/OSEL/FDA)

26. Using the University of California Clinical Data Warehouse to Evaluate the Safety and Efficacy of Biologics, including Blood Transfusions, Vaccines, CAR-T cell Therapies, and other CBER regulated Products

Atul Butte, MD, PhD (UCSF)

Barbee Whitaker, PhD (CBER/FDA)

Steven Anderson, PhD, MPP (CBER/FDA)

Artur Belov, PhD (CBER/FDA)

27. TOBIAS – A Clinical Decision Support tool to Personalize NGS Diagnostic Test Results based on Genetic Ancestry

Snehit Prabhu, PhD (Stanford)

Elaine Johanson (OHI/FDA)

Zivana Tezak, PhD (CDRH/FDA)

Richardae Araojo, PharmD (OMHHE/FDA)

Christine Lee, PharmD, PhD (OMHHE/FDA)

28. HYDRA – a Federated Computational Infrastructure to Enable Inclusive, Large-scale Precision Medicine Studies

Snehit Prabhu, PhD (Stanford)

Elaine Johanson (OHI/FDA)

Zivana Tezak, PhD (CDRH/FDA)

Richardae Araojo, PharmD (OMHHE/FDA)

Christine Lee, PharmD, PhD (OMHHE/FDA)

29. HIV Genomic Surveillance in Cameroon by Next-Generation Sequencing Charles Chiu, MD, PhD (UCSF) Indira Hewlett, PhD (CBER/FDA)
30. Characterizing Population-Specific Clinical Asthma Profiles Esteban Burchard, MD, MPH (UCSF) Richardae Araojo, PharmD (OMHHE/FDA)
31. Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP) Kathy Giacomini, PhD (UCSF)
Shiew Mei Huang, PhD (CDER/FDA)
Qi Liu, PhD (CDER/FDA)
Lei Zhang, PhD (CDER/FDA)
32. Data Science Methods for Post-marketing Surveillance of AI Diagnostic Tools Daniel Rubin, MD, MS (Stanford)
Qi Liu, PhD, MStat, FCP (CDER/FDA)
Yaning Wang, PhD, Mstat (CDER/FDA)
Hao Zhu, PhD, Mstat (CDER/FDA)
M. Khair ElZarrad PHD, MPH (CDER/FDA)
Matthew Diamond, MD, PhD (CDRH/FDA)
33. Identifying Genetic Mechanisms of Doxorubicin-Induced Cardiotoxicity Joseph Wu, MD, PhD (Stanford)
Bridget Nugent, PhD (OWH/FDA)
Alexandre Ribeiro, PhD (CDER/DARS/FDA)
34. The Effect of Excipients on the Oral Absorption of Fexofenadine in Humans Kathy Giacomini, PhD (UCSF)
Lei Zhang, PhD (CDER/OGD/FDA)
Eleftheria Tsakalozou, PhD (CDER/OGD/FDA)
35. Assessment of Patient Tolerance for Risk Associated with High Intensity Focused Ultrasound (HIFU) for the Ablation of Prostate Tissue

Geoffrey Sonn, MD (Stanford)

Charles Viviano, MD, PhD (CDRH/FDA)
David Gebben, PhD (CDRH/FDA)
Olufemi Babalola, Msc., MHS (CDRH/FDA)
36. Usability Testing of Virtual Reality for Opioid-Sparing Pain Management Among Diverse Patients
Urmimala Sarkar, MD, MPH (UCSF)
Courtney Lyles, PhD (UCSF)
Richardae Araojo, PharmD, MS (OMHHE/FDA)
Christine Lee, PharmD, PhD (OMHHE/FDA)
Michelle Tarver, MD, PhD (CDRH/FDA)

Research Projects: Completed

Research project name

Lead scientist at UCSF & Stanford University

FDA collaborators​/​non-federal entities collaboratorS

37. Improving Efficiency and Rigor of Pharmacovigilance at FDA

Russ Altman, MD, PhD (Stanford)

Steve Anderson, PhD, MPP (CBER/FDA)
Robert Ball, MD, MPH (CDER/FDA)
Ruth Barratt, PhD, DVM (CDER/FDA)
Mitra Rocca, Dipl. Inform. Med. (CDER/FDA)
Carol Pamer, RPh, MPH (CDER/FDA)
Scott Proestel, MD (CDER/FDA)

38. Precision Medicine Initiative

Russ Altman, MD, PhD (Stanford)

Elaine Johanson (OHI/FDA)

39. Next Generation Text Analytics for FDA-Relevant Text Mining Russ Altman, MD, PhD (Stanford)
Roselie Bright, ScD (OHI/FDA)
Larry Callahan, PhD (OHI/FDA)
Elaine Johanson (OHI/FDA)
Frank Switzer, PhD (OHI/FDA)
40. Use of NLP/Machine Learning to Analyze Medication Error Reports Russ Altman, MD, PhD (Stanford)
Sonja Brajovic, MD (OSE/RSS/CDER/FDA)
Todd Bridges, RPh (OSE/DMEPA/CDER/FDA)
Carol Pamer, RPh, MPH (CDER/FDA)
41. Network Integration for Precision Medicine Drug Models

Russ Altman, MD, PhD (Stanford)

Jennifer Wilson, PhD (Stanford)

Michael Pacanowski, PharmD, MPH (CDER/FDA)
Anuradha Ramamoorthy, PhD (CDER/FDA)
Oluseyi Adeniyi, PhD (CDER/FDA)

42. Renal Impairment in New Drug Development

Kathy Giacomini, PhD (UCSF)

Timothy Meyer, MD (Stanford)

Ruth Barratt, PhD, DVM (CDER/FDA)
Lei Zhang, PhD (CDER/FDA)
Shiew Mei Huang, PhD (CDER/FDA)
Issam Zineh, PharmD, MPH (CDER/FDA)
Ming-Liang Tan, PhD (CDER/FDA)

43. Improving the Diagnostic Accuracy of ADR Signal Detection

Nigam Shah, MBBS, PhD (Stanford)

Ruth Barratt, PhD, DVM (CDER/FDA)
Henry Francis, MD (CDER/FDA)
Ana Szarfman, MD, PhD (CDER/FDA)
Isaac Chang, MD, PhD (CDRH/FDA)
Joseph Tonning, MD (CDER/FDA)
Robert Ball, MD, MPH (CDER/FDA)
Mitra Rocca, Dipl. Inform. Med. (CDER/FDA)

44. Single Cell Mass Cytometry Based Assessment of MSCs

Sean Bendall, PhD (Stanford)

Steven Bauer, PhD (CBER/FDA)

45. Spinal Orthopedic Device Mechanics

Jeff Lotz, PhD (UCSF)

Anton Dmitriev, PhD (CDRH/FDA)
Srinidhi Nagaraja, PhD (CDRH/FDA)
Jonathan Peck, MS (CDRH/FDA)

46. Methods to Inactivate Pathogens in Blood

Eric Kool, PhD (Stanford)

Jaroslav Vostal, MD, PhD (CBER/FDA)
Chintamani Atreya,PhD (CBER/FDA)
47. Knowledge Synthesis - Gut Microbiome Peter Turnbaugh, PhD (UCSF)
Roselie Bright, ScD, MS, PMP (OHI/FDA)
Elaine Johanson (OHI/FDA)

48. Chemoinformatic Tools to Predict the Effects of Excipients in Generic Drugs

Excipient Browser (a new research tool to help investigate and improve these important substances)

Usage Statistics of Excipient Browser

Brian Shoichet, PhD (UCSF)
Andrew Babiskin, PhD (CDER/FDA)
Robert Dorsam, PhD (CDER/FDA)
Victoria Keck, MHA (CDER/FDA)
Zhanglin Ni, PhD (CDER/FDA)
Eleftheria Tsakalozou, PhD, CDER/FDA
Liang Zhao, PhD (CDER/FDA)
Susan Zuk, MS (CDER/FDA)
Bryan Roth, MD, PhD (University of North Carolina, Chapel Hill) (in kind)
Laszio Urban, MD, PhD (Novartis) (in kind)
49. Mapping a Better Approach to Obtaining Pediatric Patient Preferences Korey Hood, PhD (Stanford)
Heather Benz, PhD (CDRH/FDA)
Martin Ho, MSc (CDRH/FDA)
Vasum Peiris, MD, MPH (CDRH/FDA)
Anindita Saha (CDRH/FDA)
50. OneSource

Laura Esserman, MD, MBA (UCSF)

Ronald Fitzmartin, PhD, MBA (CDER/FDA)
Fatima Frye (CDER/FDA)
Mitra Rocca, Dipl. Inform. Med. (CDER/FDA)
MaryAnne Slack (CDER/FDA)


February 10, 2020

Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP

Molecular Pharmaceutics 2020, 17, 3, 748-756

Authors: Zou L, Pottel J, Khuri N, Ngo HX, Ni Z, Tsakalozou E, Warren MS, Huang Y, Shoichet BK, Giacomini KM

November 26, 2019

Patient-Reported Outcomes Measures and Patient Preferences for Minimally Invasive Glaucoma Surgical Devices

Eye, Volume 34, pp. 205-210, 2020

Authors: Tianjing Li, T. Le, Ronald D. Hays, Qi N. Cui, Malvina Eydelman, George Spaeth, Michelle E. Tarver & Kuldev Singh

June 1, 2019

In Vitro Models for Thrombogenicity Testing of Blood-Recirculating Medical Devices

Expert Review of Medical Devices, Volume 16, 2019 - Issue 7

Authors: Sarode DN, Roy S

May 25, 2019

A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization

Clinical Pharmacology & Therapeutics, Volume 106, Number 5, November 2019

Authors: Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn ACJM, Simons-Oosterhuis Y, Tibboel D, Samsom JN, Verdijk RM, Smeets B, Zhang L, Huang SM, Giacomini KM, de Wildt SN

May 22, 2019

PathFXweb: A Web Application for Identifying Drug Safety and Efficacy Phenotypes

Bioinformatics, Volume 35, Issue 21, 1 November 2019, Pages 4504–4506​

Authors: Jennifer L Wilson, Mike Wong, Ajinkya Chalke, Nicholas Stepanov, Dragutin Petkovic, Russ B Altman

February 17, 2019

Research Projects Supported by the University of California, San Francisco-Stanford Center of Excellence in Regulatory Science and Innovation

Clinical Pharmacology & Therapeutics, Volume 105, Number 4, pp. 815-818, April 2019

Authors: Kathleen M. Giacomini, Lawrence Lin, Russ B. Altman

January 20, 2019

Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters

Clinical Pharmacology & Therapeutics, Vol. 105, Number 2, pp. 323-325, February 2019

Authors: Ling Zou, Zhanglin Ni, Eleftheria Tsakalozou, Kathleen M. Giacomini

December 7, 2018

PathFX Provides Mechanistic Insights into Drug Efficacy and Safety for Regulatory Review and Therapeutic Development

PLOS Computational Biology, Vol. 14, Issue 12: e.1006614

Authors: Jennifer L. Wilson, Rebecca Racz, Tianyun Liu, Oluseyi Adeniyi, Jielin Sun, Anuradha Ramamoorthy, Michael Pacanowski, Russ Altman

September 27, 2018

Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes

BMC Cancer, 2018 18:933

Authors: López-Pineda A, Rodríguez-Moran MF, Álvarez-Aguilar C, Fuentes Valle SM, Acosta-Rosales R, Bhatt AS, Sheth SN, Bustamante CD

August 6, 2018

Network Enhancement as a General Method to Denoise Weighted Biological Networks

Nature Communications 9, Article number: 3108 (2018)

Authors: Wang B, Pourshafeie A, Zitnik M, Zhu J, Bustamante CD, Batzoglou S, Leskovec J

August, 2018

Machine Learning in Chemoinformatics and Drug Discovery

Drug Dicovery Today, Volume 23, Issue 8, Pages 1538-1546, August 2018

Authors: Lo YC, Rensi SE, Torng W, Altman RB

February 2, 2018

Biomarkers: Delivering on the Expectation of Molecularly Driven, Quantitative Health

Experimental Biology Medicine, Vol. 243, Issue 3, pp. 313-322

Authors: Wilson JL, Altman RB

January 17, 2018

Chemical Reaction Vector Embeddings: Towards Predicting Drug Metabolism in the Human Gut Microbiome

Pacific Symposium of Biocomputing, Vol. 23, pp. 56-67

Authors: Mallory EK, Acharya A, Rensi SE, Turnbaugh PJ, Bright RA, Altman RB

March 21, 2017

Development of an Automated Assessment Tool for MedWatch Reports in the FDA Adverse Event Reporting System

Journal of the American Medical Informatics Association

Authors: Han L, Ball R, Pamer CA, Altman RB, Proestel S

March 21, 2017

Mechanical Performance of Cervical Intervertebral Body Fusion Devices: A Systematic Analysis of Data Submitted to the Food and Drug Administration

Journal of Biomechanics, Vol. 54, pp. 26-32

Authors: Peck JH, Sing DC, Nagaraja S, Peck DG, Lotz JC, Dmitriev AE

October 27, 2016

From the Patient's Point of View, How Should Minimally Invasive Glaucoma Surgeries be Evaluated?

American Journal of Ophthalmology, Vol. 172, pp. 12-14

Authors: Qui N. Cui, Kuldev Singh, George L. Spaeth

August 24, 2016

A Molecular Basis for Innovation in Drug Excipients

Clinical Pharmacology & Therapeutics, Vol. 101, Issue 3, pp. 320-323

Authors: John J. Irwin, Joshua Pottel, Ling Zou, Hong Wen, Susan Zuk, Xinyuan Zhang, Teague Sterling, Brian K., Shoichet, Robert Lionberger, Kathleen M. Giacomini

July 28, 2016

Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3

Molecular Pharmaceutics, Vol. 12, Issue 9, pp. 3130-40

Authors: Chia-Hsiang Hsueh, Kenta Yoshida, Ping Zhao, Timothy W Meyer, Lei Zhang, Shiew-Mei Huang, Kathleen M Giacomini

April 20, 2016

A Research Roadmap for Next Generation Sequencing Informatics

Science Translational Medicine, Vol. 8, Issue 335, pp. 10

Authors: Altman RB, Prabhu S, Sidow A, Zook JM, Goldfeder R, Litwack D, Ashley E, Asimenos G, Bustamante DC, Donigan K, Giacomini KM, Johansen E, Khuri N, Lee E, Liang XS, Salit M, Serang O, Tezak Z, Wall DP, Mansfield E, Kass-Hout T

November 25, 2015

Unmet Needs: Research Helps Regulators do their Jobs

Science Translational Medicine, Vol. 7, Issue 315, pp. 22

Authors: Altman RB, Khuri N, Salit M, Giacomini KM

July 31, 2015

A Method for Systematic Discovery of Adverse Drug Events from Clinical Notes

Journal of the American Medical Informatics Association, Vol. 22, Issue 6, pp. 1196-204

Authors: Wang G, Jung K, Winnenberg R, Shah NIH